1. Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice

   • Ornella Letari
   • Catherine Booth
   • Gianfranco Caselli

   Original Article Open access 30 December 2009 Pages: 819 - 827

   

2. A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer

   • A. Sabharwal
   • P. G. Corrie
   • M. R. Middleton

   Original Article 29 December 2009 Pages: 829 - 835

3. Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

   • Salvatore Del Prete
   • Liliana Montella
   • Raffaele Addeo

   Original Article 30 December 2009 Pages: 837 - 844

   

4. A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group

   • M. M. Moore
   • M. Stockler
   • M. J. Boyer

   Original Article 16 January 2010 Pages: 845 - 850

5. Syl611, a novel semisynthetic taxane derivative, reverses multidrug resistance by p-glycoprotein inhibition and facilitating inward transmembrane action

   • Yi Zhang
   • Hongyan Li
   • Xiaoguang Chen

   Original Article 06 January 2010 Pages: 851 - 859

   

6. A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer

   • Jalid Sehouli
   • Oumar Camara
   • Guelten Oskay-Oezcelik

   Original Article 07 January 2010 Pages: 861 - 868

7. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

   • Scott Ackler
   • Michael J. Mitten
   • Alexander R. Shoemaker

   Original Article 23 January 2010 Pages: 869 - 880

   

8. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo

   • Caroline D. Scatena
   • Jeffrey L. Kumer
   • Jeffrey A. Silverman

   Original Article 08 January 2010 Pages: 881 - 888

   

9. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer

   • Jung Hye Kwon
   • Jung Han Kim
   • Dae Young Zang

   Original Article 21 January 2010 Pages: 889 - 897

   

10. Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1α

    • Sreenivasulu Chintala
    • Károly Tόth
    • Youcef M. Rustum

    Original Article 12 January 2010 Pages: 899 - 911

    

11. Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer

    • Kazuhiro Yanagihara
    • Kenichi Yoshimura
    • Masanori Fukushima

    Original Article 13 January 2010 Pages: 913 - 918

    

12. A general process for the development of peptide-based immunoassays for monoclonal antibodies

    • Ana B. Sanchez
    • Tammy Nguyen
    • Bradley T. Messmer

    Original Article Open access 20 January 2010 Pages: 919 - 925

    

13. Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors

    • Robert J. Morgan
    • Timothy Synold
    • James H. Doroshow

    Original Article 28 January 2010 Pages: 927 - 933

14. Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors

    • Yasuhito Fujisaka
    • Yasuhide Yamada
    • Mitsuo Seki

    Original Article 28 January 2010 Pages: 935 - 943

    

15. Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression

    • Dilip Jain
    • Nila Patel
    • Wolfram Siede

    Original Article 26 January 2010 Pages: 945 - 952

    

16. Down-regulation of lipids transporter ABCA1 increases the cytotoxicity of Nitidine

    • Hironori Iwasaki
    • Takafumi Okabe
    • Hirosuke Oku

    Original Article 18 March 2010 Pages: 953 - 959

    

17. Phase II study of pemetrexed in patients with advanced neuroendocrine tumors

    • Jennifer A. Chan
    • Andrew X. Zhu
    • Matthew H. Kulke

    Original Article 04 February 2010 Pages: 961 - 968

    

18. Increased anticoagulant activity of warfarin used in combination with doxifluridine

    • Masaru Nakajima
    • Tomoo Genda
    • Yasufumi Sawada

    Original Article 28 January 2010 Pages: 969 - 972

    

19. The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors

    • Brian S. Choi
    • Dona B. Alberti
    • Kyle D. Holen

    Original Article 02 February 2010 Pages: 973 - 980

20. Antitumor effects of recombinant human Interleukin-6 on mouse bladder carcinoma through Fas-mediated apoptosis

    • Chuan-gang Li
    • Mo-lin Li
    • Wen-sen Wu

    Original Article 25 May 2010 Pages: 981 - 986

    

21. A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer

    • Manabu Shiozawa
    • Makoto Akaike
    • Soichiro Morinaga

    Clinical Trial Report 10 July 2010 Pages: 987 - 992

    

22. Relationship among pharmacokinetics and pharmacodynamics of fenretinide and plasma retinol reduction in neuroblastoma patients

    • Franca Formelli
    • Elena Cavadini
    • Stefano Persiani

    Short Communication 08 June 2010 Pages: 993 - 998

    

23. C6 ceramide potentiates curcumin-induced cell death and apoptosis in melanoma cell lines in vitro

    • Teng Yu
    • Jinchao Li
    • Hui Sun

    Short Communication 03 June 2010 Pages: 999 - 1003